Pneumocystis pneumonia in solid organ transplant recipients: Not yet an infection of the past

Transplant Infectious Disease

Volumn 14, Issue 5, 2012, Pages 519-525

  Wang, E H Z ^a   Partovi, N ^a,b   Levy, R D ^a,b   Shapiro, R J ^a,b   Yoshida, E M ^a,b   Greanya, E D ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Immunosuppression; Pneumocystis jirovecii; Pneumonia; Solid organ transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HUMAN; HYPERKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; VIREMIA;

ADULT; AGED; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; YOUNG ADULT;

EID: 84867644057     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00740.x     Document Type: Article

References (31)

1. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350 (24): 2487-2498.
2. Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322 (3): 161-165.
3. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 1-207.
4. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995; 155 (11): 1125-1128.
5. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42 (5): 995-1004.
6. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28 (2): 240-246.
7. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17 (4): 770-782.
8. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S227-S233.
9. Phipps LM, Kable K, Halliday CL, et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Lancet Infect Dis 2011; 92: 1327-1334.
10. Bourbigot B, Bensoussan T, Garo B, et al. CD4 T-lymphocyte counts as predictors of pneumonia after kidney transplantation. Transplant Proc 1993; 25 (1 Pt 2): 1491-1492.
11. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34 (8): 1098-1107.
12. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113 (5): 1215-1224.
13. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007; 3: CD005590.
14. Hardy AM, Wajszczuk CP, Suffredini AF, Hakala TR, Ho M. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis 1984; 149 (2): 143-147.
15. Dummer JS. Pneumocystis carinii infections in transplant recipients. Semin Respir Infect 1990; 5 (1): 50-57.
16. Elinder CG, Andersson J, Bolinder G, Tyden G. Effectiveness of low-dose cotrimoxazole prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas transplantation. Transpl Int 1992; 5 (2): 81-84.
17. Hennequin C, Page B, Roux P, Legendre C, Kreis H. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol 1995; 14 (2): 122-126.
18. Branten AJ, Beckers PJ, Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrol Dial Transplant 1995; 10 (7): 1194-1197.
19. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996; 62 (3): 421-423.
20. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22 (6): 920-925.
21. Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004; 4 (Suppl 10): 135-141.
22. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 2002; 17 (Suppl 4): 36-39.
23. Catherinot E, Lanternier F, Bougnoux M-E, Lecuit M, Coudec LJ, Lotholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am 2010; 24 (1): 107-138.
24. Cushion MT. Are members of the fungal genus pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above? PLoS Pathog 2010; 6 (9): e1001009.
25. Monnet X, Vidal-Petiot E, Osman D, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 2008; 12 (1): R28.
26. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88 (1): 135-141.
27. O'Gara MJ, Lee CH, Weinberg GA, Nott JM, Queener SF. IMP dehydrogenase from Pneumocystis carinii as a potential drug target. Antimicrob Agents Chemother 1997; 41 (1): 40-48.
28. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175 (4): 901-904.
29. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68 (10): 1526-1532.
30. Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70 (8): 1244-1247.
31. Anand S, Samaniego M, Kaul DR. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis. Transpl Infect Dis 2011; 13 (6): 570-574.